Quality of life in hereditary neuropathy with liability to pressure palsies is as impaired as in Charcot-Marie-Tooth disease type 1A.
Ability
Charcot–Marie–Tooth type 1A (CMT1A)
Hereditary neuropathy with liability to pressure palsies (HNPP)
Impairment
Quality of life
Journal
Acta neurologica Belgica
ISSN: 2240-2993
Titre abrégé: Acta Neurol Belg
Pays: Italy
ID NLM: 0247035
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
28
01
2020
accepted:
06
04
2020
pubmed:
27
4
2020
medline:
23
2
2022
entrez:
27
4
2020
Statut:
ppublish
Résumé
To date, only one study assessed quality of life (QoL) in patients with hereditary neuropathy with liability to pressure palsies (HNPP). We aimed to fill in this gap by investigating QoL in a cohort of patients with HNPP compared to Charcot-Marie-Tooth type 1A (CMT1A) patients, as well as to analyze sociodemographic and clinical features associated with QoL in HNPP. Eighteen genetically confirmed HNPP patients were age-and gender-matched with 18 CMT1A patients. SF-36 questionnaire was used to assess QoL. Medical Research Council (MRC) Sum Score, CMT Neuropathy Score (CMTNS), Overall Neuropathy Limitation Scale Score (ONLS), Falls Efficacy Score (FES), Visual Analog Pain Scale, Beck Depression Inventory (BDI) and Fatigue Severity Scale (FSS) were also used in our study. Although HNPP patients were less clinically impaired, no difference was observed in these two cohorts regarding SF-36 scores. Worse QoL in HNPP patients was associated with lower education (p < 0.01), physical work (p < 0.05), higher number of clinically affected nerves during the disease course (p < 0.01), worse MRC-SS score (p < 0.01), worse ONLS score (p < 0.01), and with more severe pain (p < 0.01), depression (p < 0.01), and fatigue (p < 0.01). Worse pain at the moment of testing appeared as a significant independent predictor of worse QoL in HNPP patients (β = - 0.93, p < 0.001). QoL was similarly impaired in patients with HNPP and patients with CMT1A. We identified different factors associated with QoL in HNPP, and many of these factors are amenable to treatment which is of special interest in these still incurable disease.
Identifiants
pubmed: 32335868
doi: 10.1007/s13760-020-01355-w
pii: 10.1007/s13760-020-01355-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1481-1486Subventions
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : 175083
Informations de copyright
© 2020. Belgian Neurological Society.
Références
Ramchandren S (2017) Charcot–Marie–Tooth disease and other genetic polyneuropathies. Continuum (Minneap Minn) 23(5):1360–1377
Attarian S, Fatehi F, Rajabally YA et al (2019) Hereditary neuropathy with liability to pressure palsies. J Neurol. https://doi.org/10.1007/s00415-019-09319-8
doi: 10.1007/s00415-019-09319-8
pubmed: 31089861
pmcid: 6394805
Cordeiro JL, Marques W, Hallak JE, Osório FL (2014) Charcot–Marie–Tooth disease, psychiatric indicators and quality of life: a systematic review. ASN Neuro 6(3):185–192
doi: 10.1042/AN20130048
Vinci P, Serrao M, Millul A, Deidda A, De Santis F, Capici S, Martini D, Pierelli F, Santilli V (2005) Quality of life in patients with Charcot–Marie–Tooth disease. Neurology 65(6):922–924
doi: 10.1212/01.wnl.0000176062.44360.49
Padua L, Aprile I, Cavallaro T, Commodari I, La Torre G, Pareyson D, Quattrone A, Rizzuto N, Vita G, Tonali P, Schenone A (2006) Variables influencing quality of life and disability in Charcot–Marie–Tooth (CMT) patients: Italian multicentre study. Neurol Sci 27(6):417–423
doi: 10.1007/s10072-006-0722-8
Padua L, Shy ME, Aprile I, Cavallaro T, Pareyson D, Quattrone A, Rizzuto N, Vita G, Tonali P, Schenone A (2008) Correlation between clinical/neurophysiological findings and quality of life in Charcot–Marie–Tooth type 1A. J Peripher Nerv Syst 13(1):64–70
doi: 10.1111/j.1529-8027.2008.00159.x
Redmond AC, Burns J, Ouvrier RA (2008) Factors that influence health-related quality of life in Australian adults with Charcot–Marie–Tooth disease. Neuromuscul Disord 18(8):619–625
doi: 10.1016/j.nmd.2008.05.015
Boentert M, Dziewas R, Heidbreder A, Happe S, Kleffner I, Evers S, Young P (2010) Fatigue, reduced sleep quality and restless legs syndrome in Charcot–Marie–Tooth disease: a web-based survey. J Neurol 257(4):646–652
doi: 10.1007/s00415-009-5390-1
Calvert M, Pall H, Hoppitt T, Eaton B, Savill E, Sackley C (2013) Health-related quality of life and supportive care in patients with rare long-term neurological conditions. Qual Life Res 22(6):1231–1238
doi: 10.1007/s11136-012-0269-5
Padua L, Aprile I, Cavallaro T, Commodari I, Pareyson D, Quattrone A, Rizzuto N, Vita G, Tonali P, Schenone A (2008) Relationship between clinical examination, quality of life, disability and depression in CMT patients: Italian multicenter study. Neurol Sci 29(3):157–162
doi: 10.1007/s10072-008-0928-z
Padua L, Pazzaglia C, Cavallaro T, Commodari I, Pareyson D, Quattrone A, Rizzuto N, Vita G, Tonali PA, Schenone A (2007) Quality of life is not impaired in patients with hereditary neuropathy with liability to pressure palsies. Eur J Neurol 14(1):e45–e46
doi: 10.1111/j.1468-1331.2006.01545.x
Aarskog NK, Vedeler CA (2000) Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot–Marie–Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 107(5):494–498
doi: 10.1007/s004390000399
Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerv 14(11):1103–1109
doi: 10.1002/mus.880141111
Shy ME, Blake J, Krajewski K et al (2005) Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64(7):1209–1214
doi: 10.1212/01.WNL.0000156517.00615.A3
Graham R, Hughes R (2006) A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 77(8):973–976
doi: 10.1136/jnnp.2005.081547
Williamson A, Hoggart B (2005) Pain: a review of three commonly used pain rating scales. J Clin Nurs 14(7):798–804
doi: 10.1111/j.1365-2702.2005.01121.x
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123
doi: 10.1001/archneur.1989.00520460115022
Beck AT, Steer RA, Carbin MG (1988) Psychometric properties of the beck depression inventory: twenty-fve years of evaluation. Clin Psychol Rev 8(1):77–100
doi: 10.1016/0272-7358(88)90050-5
Tinetti M, Richman D et al (1990) Falls efficacy as a measure of fear of falling. J Gerontol 45(6):P239
doi: 10.1093/geronj/45.6.P239
SF-36 Health Survey (original version) language recalls. https://www.qualitymetric.com . Accessed December 2019.
Pfeiffer G, Wicklein EM, Ratusinski T, Schmitt L, Kunze K (2001) Disability and quality of life in Charcot-Marie-Tooth disease type 1. J Neurol Neurosurg Psychiatry 70:548–550
doi: 10.1136/jnnp.70.4.548
Vinci P, Gargiulo P, Panunzi M, Baldini L (2009) Psychological distress in patients with Charcot–Marie–Tooth disease. Eur J Phys Rehabil Med 45:385–389
pubmed: 19182736
Phillips MF, Steer HM, Soldan JR, Wiles CM, Harper PS (2009) Daytime somnolence in myotonic dystrophy. J Neurol 246:275–282
doi: 10.1007/s004150050346
Kalkman JS, Schillings ML, Zwarts MJ, Van Engelen BGM, Bleijenberg G (2007) Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I. Acta Neurol Scand 115:265–270
doi: 10.1111/j.1600-0404.2006.00737.x
Murphy SM, Herrmann DN, McDermott MP, Scherer SS, Shy ME, Reilly MM, Pareyson D (2011) Reliability of the CMT neuropathy score (second version) in Charcot–Marie–Tooth disease. J Peripher Nerv Syst 16(3):191–198
doi: 10.1111/j.1529-8027.2011.00350.x